Group 1 - The company held its 10th meeting of the 4th Supervisory Board on June 6, 2025, with all three supervisors present, confirming the meeting's legality and effectiveness [1][2] - The Supervisory Board decided to waive the notice period for the meeting, with all votes in favor of the agenda [1] - The board approved the company's provision of guarantees for its wholly-owned subsidiary, stating that this is a normal business operation and does not harm the interests of the company or its shareholders [2]

申万宏源证券承销保荐有限责任公司 关于重庆正川医药包装材料股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"保荐人"）作为重庆正川 医药包装材料股份有限公司（以下简称"公司"或"正川股份"）公开发行可转 换公司债券的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券交易所上 市公司自律监管指引第1号—规范运作》以及《上海证券交易所上市公司自律监 管指引第11号—持续督导》等有关规定等有关规定对正川股份使用部分闲置募集 资金进行现金管理的事项进行了核查，具体如下： 一、公司公开发行可转换公司债券募集资金基本情况 经中国证券监督管理委员会《关于核准重庆正川医药包装材料股份有限公司 公开发行可转换公司债券的批复》（证监许可2021198 号）核准，公司于 2021 年 4 月 28 日公开发行可转换公司债券 405 万张，每张面值 100 元人民币。本次 发 行 可 转 换 公 司 债 券 募 集 资 金 总 额 405,000,000 元 ， 扣 除 发 行 费 人 民 币 募集资金已于 2 ...

Group 1 - The company held a supervisory board meeting on June 4, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1] - The supervisory board approved the use of up to 15 million RMB of idle raised funds for cash management, ensuring the safety and efficiency of fund usage [1] - The company plans to invest idle self-owned funds in cash management, with a maximum daily balance of 300 million RMB, focusing on low-risk investment products [2] Group 2 - The company intends to establish a wholly-owned subsidiary in Hong Kong, named Zhengchuan International (Hong Kong) Co., Ltd., with an investment amount of 500,000 USD [3]

Group 1: Company Performance - In 2024, the company achieved a historical high in revenue of 1.081 billion CNY, representing a year-on-year growth of 14.09% [3] - The net profit attributable to shareholders remained stable at 66.07 million CNY, consistent with the previous year [3] - Total assets reached 2.356 billion CNY, reflecting a year-on-year increase of 9.54% [3] Group 2: Business Strategy and Outlook - The company focuses on the pharmaceutical packaging and heat-resistant glass sectors, aiming to strengthen its position as a market leader [2] - There is an ongoing expansion of production capacity for borosilicate products, with expectations for continued growth in the future [3] - The company plans to enhance its market share in the pharmaceutical packaging sector by leveraging its technical reserves and customer resources [3] Group 3: Share Buyback and Financial Management - As of May 13, the company has repurchased 2,325,800 shares, accounting for 1.00% of the total share capital [4] - The buyback plan will continue based on market conditions [4] Group 4: International Expansion - The company has prioritized global development, with significant progress in Latin America and the Middle East [5] - In January 2024, the company signed an investment framework agreement to acquire 51% of The European Ampoules Company in Egypt [5] - A cooperation investment agreement was signed with SANTISA ABORATORIO FARMACEUTICO S/A in March 2025 to further expand market reach [6]

Group 1: Financial Performance - The company's revenue for 2024 is projected to grow by 14.09% compared to 2023, driven by strong market demand and strategic focus on pharmaceutical packaging [2] - Research and development (R&D) investment for 2024 is set at 33.79 million RMB, reflecting a 12.16% increase from 2023 [3] Group 2: Business Strategy - The company aims to expand its production capacity and enhance market development efforts, particularly in pharmaceutical packaging [2][7] - Plans to accelerate the transformation of high borosilicate glass business and focus on new product development and channel expansion [4][7] Group 3: International Expansion - The company is prioritizing global development, with a focus on Latin America and the Middle East, having signed investment agreements in Egypt and Brazil [5][6] Group 4: Internal Management and Risk Mitigation - Continuous improvement in internal management is a key focus, including the introduction of high-level talent and enhancement of digital and automated processes to reduce production costs [8] - The company plans to establish independent subsidiaries for brand promotion and sales, enhancing its market presence [4][8] Group 5: Share Buyback Plan - The company has approved a share buyback plan, intending to repurchase between 50 million and 100 million RMB worth of its A-shares [9][10]

Core Insights - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size projected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and the rapid development of the pharmaceutical industry [2] - Long-term growth prospects for the pharmaceutical packaging market are supported by factors such as an aging population, increased health awareness, and improvements in the healthcare system, leading to a rising demand for pharmaceuticals and consequently for packaging [2] Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect drugs, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2] - It conveys important information regarding the quality, safety, and efficacy of the drugs through its design, materials, and structure [2] Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary processes [4] - The upstream sector involves the supply of raw materials such as plastics, glass, metals, and paper, which are crucial for the stability and quality of packaging materials [4] - The midstream sector processes these raw materials into various packaging forms, ensuring properties like sealing and moisture resistance [4] - The downstream sector includes pharmaceutical manufacturers and distributors who utilize these packaging materials for drug sales [4] - The industry is evolving towards environmentally friendly, intelligent, and personalized packaging solutions due to rising environmental awareness and technological advancements [4] Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation [6] - The initial stage was characterized by reliance on imports and limited technology, while the rapid expansion phase saw increased competition and the introduction of advanced management practices [6] - Currently, the industry is focused on transformation, with increased R&D investment and a shift towards eco-friendly and smart packaging solutions, marking a transition from technology catch-up to innovation leadership [6] Related Reports - The report by Zhiyan Consulting analyzes the competitive landscape and investment potential of the pharmaceutical packaging industry, aiming to identify future market trends and development potential [8] - It provides a comprehensive analysis of the industry’s operational status, import and export dynamics, and competitive structure, projecting trends for 2025 [10]

证券代码：301188 证券简称：力诺药包 公告编号：2025-045 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 山东力诺医药包装股份有限公司（以下简称"公司"）于2025年2月7日召开 第四届董事会第八次会议和第四届监事会第七次会议，审议通过了《关于回购公 司股份方案的议案》，拟使用公司自有资金及股票回购专项贷款资金不低于人民 币5,000万元（含），不超过人民币10,000万元通过深圳证券交易所交易系统以 集中竞价交易的方式回购公司发行的人民币普通股（A股）股票，回购价格不超 过22.00元/股（含本数），回购股份用于实施股权激励计划或者员工持股计划， 回购期限自董事会审议通过回购股份方案之日起12个月内。公司已在中国证券登 记结算有限责任公司深圳分公司开立了回购股份专用证券账户。具体内容详见公 司于2025年2月7日在巨潮资讯网披露的《关于回购公司股份方案暨取得金融机构 股票回购专项贷款承诺函的公告》（公告编号：2025-008）及公司于2025年2月 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 应当在事实发生之日起三个交易日内予以披露，现将公司回 ...

Core Viewpoint - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size expected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and increasing demand for medicines due to aging population and improved healthcare systems [1][11]. Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect medicines, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2]. Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary services. The upstream involves the supply of materials like plastics, glass, metals, and paper, which are crucial for the manufacturing of packaging materials [3]. Industry Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation. The industry has evolved from relying on imports to adopting advanced technologies and focusing on brand building and market expansion [6]. Current Industry Status - China is the world's largest producer of plastic products, with a production volume of 77.08 million tons in 2024. The availability and pricing of plastic products directly impact the pharmaceutical packaging industry [9][11]. Market Structure - The market structure of the pharmaceutical packaging industry is diverse, with plastic packaging holding a 48% share, followed by glass packaging at 28%, metal packaging at 11%, and rubber packaging at 7% [12]. Key Enterprises Analysis - The competitive landscape of the pharmaceutical packaging industry is diverse and intense. Key players include Shandong Pharmaceutical Glass, Zhengchuan Co., Hualan Co., Haishun New Materials, and Huqiang Technology, each with unique strengths and market positions [15][18][20]. Future Development Trends - The industry is moving towards high-end and high-performance packaging materials, focusing on new technologies and innovative designs to meet the demands of high-end pharmaceuticals [22]. - Green and environmentally friendly packaging is becoming a significant trend, with companies seeking biodegradable and recyclable materials to reduce environmental impact [23]. - The industry is also undergoing consolidation and internationalization, with companies optimizing resources and expanding into international markets to enhance competitiveness [24].

证券代码：603976 证券简称：正川股份 公告编号：2025-024 重庆正川医药包装材料股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 (一)非累积投票议案 1、议案名称：《2024年度董事会工作报告》 审议结果：通过 一、会议召开和出席情况 (一)股东大会召开的时间：2025年4月30日 (二)股东大会召开的地点：重庆市北碚区京东方大道357号正川永成研发楼三楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长邓勇先生主持，会议采用现场投票与网络投票相结合的方式进 行表决，会议的召集、召开及表决方式符合《公司法》及《公司章程》的规定。 (五)公司董事、监事和董事会秘书的出席情况 表决情况： ■ 2、议案名称：《2024年度监事会工作报告》 审议结果：通过 表决情况： ■ 3、议案名称：《20 ...

Core Viewpoint - Shanghai Haishun New Material Co., Ltd. demonstrates robust growth in 2024, achieving a revenue of 1.143 billion yuan, a year-on-year increase of 11.92%, and a net profit of 74.59 million yuan, showcasing its resilience in a complex market environment through technological innovation and strategic layout [1][2]. Group 1: Pharmaceutical Packaging - The company holds 161 drug packaging material registration numbers and 31 DMF filings, serving renowned pharmaceutical companies such as China National Pharmaceutical Group and AstraZeneca [1]. - Core products include cold-formed composite hard films, PTP aluminum foil, and SP composite films, which are preferred materials for packaging tablets, capsules, and suppositories due to their excellent performance and quality [1]. - The subsidiary Suzhou Haishun has received multiple honors, including being recognized as a five-star cloud enterprise in Jiangsu Province, highlighting its leading position in intelligent production and green manufacturing [1]. Group 2: New Energy Materials - Haishun focuses on the independent research and development of aluminum-plastic film materials, successfully overcoming technical barriers and achieving mass supply to several lithium battery manufacturers [2]. - Aluminum-plastic film is a key material for soft-pack lithium battery packaging, directly affecting battery safety and lifespan [2]. - The company has achieved a net cash flow from operating activities of 161 million yuan in 2024, a significant increase of 60.35% year-on-year, indicating improved operational efficiency and optimized capital management [2]. Group 3: Shareholder Returns and Future Strategy - The board approved a profit distribution plan, proposing a cash dividend of 2.7 yuan per 10 shares (tax included), continuing the tradition of valuing shareholder returns [2]. - The company has repurchased shares amounting to 3% of the total share capital, reflecting management's recognition of the company's long-term value [2]. - Future strategies include deepening the synergistic development of three major sectors: pharmaceutical packaging, new energy, and new consumption, with plans to integrate smart packaging and precise drug delivery technologies in the pharmaceutical sector [2].